Systemic inflammation parameters in chronic myocarditis in patients with atrial fibrillation
E. A. Archakov,
R. E. Batalov,
O. R. Eshmatov,
M. S. Khlynin,
T. A. Atabekov,
I. V. Stepanov,
S. V. Popov https://doi.org/10.15829/1560-4071-2025-6663
EDN: PCZAEQ
Abstract
Aim. To evaluate parameters of the systemic inflammatory response in myocarditis in patients with atrial fibrillation.
Material and methods. The study sample included 63 patients undergoing inpatient interventional treatment for atrial fibrillation. Of these, 49 (77,8%) were men. The median age was 46 (39; 54) years. During the catheter procedure, all patients underwent endomyocardial biopsy, followed by histological diagnosis. The role of systemic inflammation parameters in patients with and without myocarditis was retrospectively assessed.
Results. Chronic myocarditis was detected in 30 patients (46,1%). The systemic inflammatory response index (SIRI) (p=0,04), total systemic inflammation index (SII) (p=0,02), and monocyte-to-lymphocyte ratio (MLR) (p=0,02) were significantly higher in the group without myocarditis. ROC curves for these parameters were analyzed. Multiple regression analysis revealed no predictive effect of these factors on myocarditis.
Conclusion. The SIRI, SII, and MLR values were significantly higher in patients without myocarditis. The MLR was higher in patients with stage 2 and higher myocardial fibrosis. The SIRI and MLR were significantly lower in patients with higher EHRA score.
About the Authors
E. A. Archakov
Cardiology Research Institute, Tomsk National Research Medical Center
Russian Federation
Russian Federation
Kievskaya str., 111a, Tomsk, 634012
R. E. Batalov
Cardiology Research Institute, Tomsk National Research Medical Center
Russian Federation
Russian Federation
Kievskaya str., 111a, Tomsk, 634012
O. R. Eshmatov
Cardiology Research Institute, Tomsk National Research Medical Center
Russian Federation
Russian Federation
Kievskaya str., 111a, Tomsk, 634012
M. S. Khlynin
Cardiology Research Institute, Tomsk National Research Medical Center
Russian Federation
Russian Federation
Kievskaya str., 111a, Tomsk, 634012
T. A. Atabekov
Cardiology Research Institute, Tomsk National Research Medical Center
Russian Federation
Russian Federation
Kievskaya str., 111a, Tomsk, 634012
I. V. Stepanov
Cardiology Research Institute, Tomsk National Research Medical Center
Russian Federation
Russian Federation
Kievskaya str., 111a, Tomsk, 634012
S. V. Popov
Cardiology Research Institute, Tomsk National Research Medical Center
Russian Federation
Russian Federation
Kievskaya str., 111a, Tomsk, 634012
References
1. Jentzer JC, Szekely Y, Burstein B, et al. Peripheral blood neutrophil-to-lymphocyte ratio is associated with mortality across the spectrum of cardiogenic shock severity. J. Crit. Care. 2022;68:50-8. doi:10.1016/j.jcrc.2021.12.005.
2. Wei X, Zhang Z, Wei J, et al. Association of systemic immune inflammation index and system inflammation response index with clinical risk of acute myocardial infarction. Front. Cardiovasc. Med. 2023;10:1248655. doi:10.3389/fcvm.2023.1248655.
3. Zhou H, Li X, Wang W, et al. Immune-inflammatory biomarkers for the occurrence of MACE in patients with myocardial infarction with non-obstructive coronary arteries. Front. Cardiovasc. Med. 2024;11:1367919. doi:10.3389/fcvm.2024.1367919.
4. Kologrivova I, Kercheva M, Panteleev O, et al. Inflammatory Indices in Patients with Myocardial Infarction Complicated by Cardiogenic Shock, and Their Interconnections with SCAI Stages and Patients’ Survival: A Retrospective Study. J Clin Med. 2025;14(12):4283. doi:10.3390/jcm14124283.
5. Archakov EA, Batalov RE, Usenkov SY, Popov SV. The experience of using non-invasive long-term ECG monitoring in patients with various cardiac arrhythmias. Siberian Journal of Clinical and Experimental Medicine. 2021;36(3):166-72. (In Russ.) doi:10.29001/2073-8552-2021-36-3-166-172. EDN: DCETIR.
6. Basso C, Calabrese F, Angelini A, et al. Classification and histological, immunohistochemical, and molecular diagnosis of inflammatory myocardial disease. Heart Fail Rev. 2013;18(6):673-81. doi:10.1007/s10741-012-9355-6.
7. Caforio AL, Pankuweit S, Arbustini E, et al. European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2013;34(33):2636-48. doi:10.1093/eurheartj/eht210.
8. Mitrofanova LB, Orshanskaya V, Ho SY, et al. Histological evidence of inflammatory reaction associated with fibrosis in the atrial and ventricular walls in a case-control study of patients with history of atrial fibrillation. Europace. 2016;18(suppl 4):iv156 iv162. doi:10.1093/europace/euw361.
9. Maisch B. Cardio-Immunology of Myocarditis: Focus on Immune Mechanisms and Treatment Options. Front Cardiovasc Med. 2019;6:48. doi:10.3389/fcvm.2019.00048.
10. Cakmak A, Cetin S, Kahraman E, et al. Evaluation of CHA2DS2-VA Score and Systemic Inflammatory Indexes in Patients with Nonvalvular Atrial Fibrillation: A Case-Control Study. J Clin Med. 2025;14(13):4601. doi:10.3390/jcm14134601.
11. Harada M, Van Wagoner DR, Nattel S. Role of inflammation in atrial fibrillation pathophysiology and management. Circ. J. 2015;79:495-502. doi:10.1253/circj.CJ-15-0138.
12. Nso N, Bookani KR, Metzl M, et al. Role of inflammation in atrial fibrillation: A comprehensive review of current knowledge. J. Arrhythm. 2021;37:1-10. doi:10.1002/joa3.12473.
13. Karakasis P, Theofilis P, Vlachakis PK, et al. Atrial Fibrosis in Atrial Fibrillation: Mechanistic Insights, Diagnostic Challenges, and Emerging Therapeutic Targets. Int. J. Mol. Sci. 2024;26:209. doi:10.3390/ijms26010209.
14. Guo Y, Lip GY, Apostolakis S. Inflammatory Biomarkers and Atrial Fibrillation: Potential Role of Inflammatory Pathways in the Pathogenesis of Atrial Fibrillation-induced Thromboembolism. Curr. Vasc. Pharmacol. 2015;13:192-201. doi:10.2174/15701611113116660165.
15. Lafuse WP, Wozniak DJ, Rajaram MVS. Role of Cardiac Macrophages on Cardiac Inflammation, Fibrosis and Tissue Repair. Cells. 2020;10(1):51. doi:10.3390/cells10010051.
16. Kubota A, Frangogiannis NG. Macrophages in myocardial infarction. Am J Physiol Cell Physiol. 2022;323(4):C1304-C1324. doi:10.1152/ajpcell.00230.2022.
17. Mabire M, Hegde P, Hammoutene A, et al. MAIT cell inhibition promotes liver fibrosis regression via macrophage phenotype reprogramming. Nat Commun. 2023;14(1):1830. doi:10.1038/s41467-023-37453-5.
18. Zhang K, Phan SH. Cytokines and pulmonary fibrosis. Biol Signals. 1996;5(4):232-9. doi:10.1159/000109195.
19. Yakovenko TV, Shubik YuV, Kostyuk GP, et al. Quality of life of patients with different types of arial fibrillation and effect of treatment of nosogenic psychic disorders. Journal of Arrhythmology. 2008;51:36-9. (In Russ.) EDN: RTRXRB.
20. Petrova GA, Regushevskaya DV, Alferova PA, et al. Quality of life of patients with paroxysmal and persistent atrial fibrillation. Journal of Arrhythmology. 2012;69(69):53-6. (In Russ.)
- This article describes systemic inflammation parameters in patients with atrial fibrillation and myocarditis.
- Systemic inflammatory response index and total systemic inflammation index were significantly higher in patients with biopsy-confirmed myocarditis.
- The monocyte-to-lymphocyte ratio was higher in patients with more severe myocardial fibrosis.
Review
For citations:
Archakov E.A., Batalov R.E., Eshmatov O.R., Khlynin M.S., Atabekov T.A., Stepanov I.V., Popov S.V. Systemic inflammation parameters in chronic myocarditis in patients with atrial fibrillation. Russian Journal of Cardiology. 2025;30(4S):6663. (In Russ.) https://doi.org/10.15829/1560-4071-2025-6663. EDN: PCZAEQ
Views:
218
JATS XML
Email this article 